Zai Lab Ltd reports results for the quarter ended June 30 - Earnings Summary
Zai Lab Ltd
9688 reported a quarterly adjusted loss of 40 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -80 cents. The mean expectation of six analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -56 cents to -35 cents per share.
Revenue rose 9.4% to $109.98 million from a year ago; analysts expected $125.01 million.
Zai Lab Ltd's reported EPS for the quarter was a loss of 40 cents.
The company reported a quarterly loss of $40.73 million.
Zai Lab Ltd shares had risen by 10.7% this quarter and gained 47.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 5.8% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Zai Lab Ltd is $55.00, about 29.6% above its last closing price of $38.72
This summary was machine generated from LSEG data August 7 at 02:55 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2025 | -0.41 | -0.40 | Beat |
Mar. 31 2025 | -0.55 | -0.40 | Beat |
Dec. 31 2024 | -0.65 | -0.80 | Missed |
Sep. 30 2024 | -0.78 | -0.42 | Beat |